Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 16/20 | 0.47 |
| ▸ | GIPR | P48546 | 6/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088332 | 0.88 | GCGR (0.47) | GCGRGIPR | |
| SCHEMBL6190395 | 0.87 | GCGR (0.58) | GCGRGIPRGLP1RKCNH2 | |
| SCHEMBL4091886 | 0.87 | GCGR (0.46) | GCGRGIPRGLP1RKCNH2 | |
| SCHEMBL4082175 | 0.84 | GCGR (0.49) | GCGRGIPR | |
| SCHEMBL4091972 | 0.83 | GCGR (0.56) | GCGRGIPRGLP1RKCNH2 | |
| SCHEMBL4095716 | 0.82 | GCGR (0.54) | GCGRGIPR | |
| SCHEMBL2663493 | 0.82 | GCGR (0.53) | GCGRGIPR | |
| SCHEMBL4082061 | 0.82 | GCGR (0.61) | GCGRGIPREPHX2 | |
| SCHEMBL6190350 | 0.81 | GCGR (0.45) | GCGRGIPR | |
| SCHEMBL4086734 | 0.80 | GCGR (0.43) | GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885EPHX2 3463/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885EPHX2 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.